Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

By sjmartinez • August 5, 2023

Maas L, Gao R, Cusumano V, Spartz E, Chowdhury R, Krishna M, Lazarev M, Melia J, Selaru F, Sharma S, Limketkai B, Parian A. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae. Dig Dis Sci. 2023 Aug 4. doi: 10.1007/s10620-023-08060-7. Epub ahead of print. PMID: 37540392.

Tags: Crohn’s disease, Digestive Diseases, General Internal Medicine, inflammatory bowel disease, Perianal disease, Perianal fistula, Publications, Resident, Tumor necrosis factor inhibitor

Distinct risk groups with different healthcare barriers and acute care use exist in the U.S. population with chronic liver disease

Wong CR, Crespi CM, Glenn B, Han SB, Macinko JA, Bastani R. Distinct risk groups with different healthcare barriers and acute care use exist in[...]

Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?

Gukovskaya AS, Lerch MM, Mayerle J, Sendler M, Ji B, Saluja AK, Gorelick FS, Gukovsky I. Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?[...]

Stricturing Crohn’s Disease: When Biologics May Help or Not?

Fansiwala K, Limketkai BN. Stricturing Crohn's Disease: When Biologics May Help or Not? Inflamm Bowel Dis. 2024 Nov 12:izae264. doi: 10.1093/ibd/izae264. Epub ahead of print.[...]